NCT06519994 - Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

January 22, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Human Immunodeficiency VirusHuman PapillomavirusCervical Precancer

Interventions

DRUG

Artesunate vaginal inserts

Subjects will self-administer 200 mg of Artesunate vaginal insert daily for 5 days, on weeks 1, 3, 5.

DRUG

Placebo vaginal inserts

Subjects will self-administer a placebo vaginal insert daily for 5 days, on weeks 1, 3, 5.

Trial Locations (1)

RECRUITING

Lumumba Sub-County Hospital KEMRI- Research Care Training Program (RCTP) Building, Kisumu